Compare Fortuna Mining Corp. Common Shares (FSM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortuna Mining Corp. Common Shares vs Spyre Therapeutics Inc. Common Stock — how do they compare? Fortuna Mining Corp. Common Shares trades at $10.42 (market cap $3.01B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.4× Fortuna Mining Corp. Common Shares's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Fortuna Mining Corp. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortuna Mining Corp. Common Shares for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FSM | SYRE | |
|---|---|---|
Market Cap | $3.01B | $7.35B |
Volume | 7,155,106 | 1,624,631 |
Sector | Basic Materials | Health |
52-Week High | $13.66 | $108.92 |
52-Week Low | $7.84 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $2.63B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortuna Mining (FSM) trades at $10.58, down 1.67% on the day, amid a bearish technical signal. The company reported strong 2025 results with $947M revenue and $287M net income, but recent quarters have missed EPS expectations. Analyst consensus is bullish with 4 buy ratings, while technical indicators show mixed signals with a bearish moving average trend but neutral oscillators.
FSM presents a value opportunity with low P/E of 8.89 and robust profitability margins, but faces risks from production volatility and execution of growth projects. The stock's near-term performance hinges on Q3 2026 earnings and progress toward its 500,000-ounce gold production target by 2028.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fortuna Mining Corp. Common Shares
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
